Instrument Inactif

Communiqués Stemline Therapeutics, Inc.

Actions

US85858C1071

Recherche biotechnologique et médicale

Communiqués

17/12/20	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	AQ
10/06/20	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
11/05/20	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
05/05/20	Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	AQ
04/05/20	STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/05/20	Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million	GL
16/03/20	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
16/03/20	Stemline Therapeutics : Reports Fourth Quarter 2019 Financial Results	AQ
13/03/20	STEMLINE THERAPEUTICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	AQ
13/03/20	Stemline Therapeutics: 4Q Earnings Snapshot	AQ
13/03/20	Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results	GL
11/03/20	Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020	GL
26/02/20	Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference	GL
14/01/20	Stemline Therapeutics : Announces Preliminary 2019 Net Revenues for ELZONRIS and Highlights Commercial and Clinical Growth Drivers	AQ
13/01/20	Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers	GL
08/01/20	Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference	GL
11/12/19	Stemline Therapeutics : Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis and Multiple Myeloma	AQ
10/12/19	Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting	GL
09/12/19	Stemline Therapeutics : Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting	AQ
09/12/19	Stemline Therapeutics : Names Robert M. Francomano Chief Commercial Officer	AQ
07/12/19	Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer	GL
06/12/19	Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting	GL
02/12/19	Stemline Therapeutics : to Present at Piper Jaffray's 31st Annual Healthcare Conference	AQ
29/11/19	Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference	GL
07/11/19	Stemline Therapeutics Reports Third Quarter 2019 Financial Results	GL